Sanofi

The award acknowledges Sanofi’s consistent efforts in creating sustainable employment opportunities for Saudi nationals while simultaneously building robust leadership capabilities across its regional operations.

Sanofi will leverage Earendil’s artificial intelligence (AI)-powered drug discovery platform to support the design and development of multiple new therapeutic assets.

Through this agreement, Sanofi will gain full ownership of Heplisav-B, a two-dose hepatitis B vaccine that received US approval in 2017 and European authorization in 2021.